Longevica Therapeutics reports a four-year, $13 million in vivo screening program at The Jackson Laboratory that followed 1,033 small molecules across more than 16,000 mice through their natural lifespans, identifying roughly 60 compounds associated with 10 to 22 percent lifespan extension and two candidate mechanisms. With a new CEO and a newly assembled scientific advisory board, the company states it is moving from data generation to clinical development. Full-lifespan mammalian phenotypic datasets of this scale remain rare and provide a different class of evidence than short-term biomarker studies.
Key Points
- 1,033 compounds screened across 16,000+ mice over full lifespans
- Roughly 60 molecules linked to 10–22% lifespan extension
- Strategy spans drug repurposing, AI target discovery, companion animal translation
Longevity Analysis
Screening across an organism's entire lifespan captures what surrogate markers cannot: whether an intervention sustains repair capacity and metabolic efficiency long enough to alter mortality trajectory. A library of 1,033 compounds tested to natural death generates signal about which molecules genuinely support regenerative function and which merely shift a measurable value in the short term — a distinction that matters when translating preclinical data into human protocols. The proposed companion animal pathway offers an intermediate validation step with lifespans short enough to read out within a commercially viable timeframe.
Original published by LT Wire.